A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROPHYLACTIC VGA039 IN ADOLESCENT AND ADULT PATIENTS WITH VON WILLEBRAND DISEASE

Registry ID

VGA039-CP002

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

VEGA THERAPEUTICS, INC

Last update

2025-12-24

Conditions

• VON WILLEBRAND DISEASE

Related clinical trials

• A PHASE III, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE
• A SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF VGA039 FOLLOWING INTRAVENOUS OR SUBCUTANEOUS ADMINISTRATION OF SINGLE ASCENDING DOSES IN HEALTHY ADULTS AND ADULT PATIENTS WITH VON WILLEBRAND DISEASE

View on source registry